Vertex Pharmaceuticals Inc (VRTX) - News Archive

As Vertex Pharmaceuticals continues its path of innovation and alignment with cutting-edge medical advancements, the company recently announced significant progress across its development program for povetacicept. This...

: Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has exhibited impressive financial growth throughout 2025, underpinned by strategic product launches and ongoing advancements in clinical programs. This article provi...

Vertex Pharmaceuticals (Nasdaq: VRTX), a leader in innovative therapies for serious diseases, is making strides in improving patient access to life-saving treatments. In a significant announcement from its London headqu...

Vertex Pharmaceuticals: Driving Innovation and Growth in Cystic Fibrosis Treatments In a compelling display of innovation and market responsiveness, Vertex Pharmaceuticals (Nasdaq: VRTX) has recently reported its second...

In the recent financial landscape, Vertex Pharmaceuticals Inc. has reported its first-quarter results for 2025, which showcased a combination of resilience and challenges. Although shares have demonstrated an overall ou...

: The European Commission s recent regulatory approval for the expanded indication of KAFTRIO in combination with ivacaftor marks a significant development in the treatment paradigm for cystic fibrosis (CF). Vertex Phar...

As the landscape of pharmaceutical innovation continues to evolve, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) stands at the forefront, making significant strides in the treatment of complex genetic disorders suc...

Vertex Pharmaceuticals Secures FDA Approval for JOURNAVX, Marks New Revenue Milestone Vertex Pharmaceuticals Incorporated has announced a significant breakthrough in pain management with the FDA s approval of JOURNAVX (...

In a significant advancement for the treatment of cystic fibrosis (CF) and beta thalassemia, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has made notable strides with the recent U.S. Food and Drug Administration...

In a significant advancement for the cystic fibrosis (CF) treatment landscape, Vertex Pharmaceuticals Incorporated recently announced the U.S. Food and Drug Administration (FDA) approval to expand the use of TRIKAFTA (e...

Vertex Pharmaceuticals Expands Treatment Options for Cystic Fibrosis and Advances Pain Management Approaches BOSTON, MA Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has made significant strides in its commitment t...

The pharmaceutical landscape is rapidly evolving, marked by breakthroughs that address critical health issues. Vertex Pharmaceuticals has made significant strides in addressing two major health conditions: painful lumbo...

In a significant advancement for patients suffering from transfusion-dependent beta thalassemia (TDT), Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cutting-edge gene-editing th...

In an epochal advancement for the pharmaceutical industry, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has heralded a pivotal moment marked by the U.S. Food and Drug Administration (FDA) acceptance of its New Dru...

Vertex Pharmaceuticals Achieves Milestones in Cystic Fibrosis and Hematological Disorder TreatmentsVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) continues to make profound strides in the landscape of pharmaceutical...

Vertex Pharmaceuticals: Achieving Breakthroughs in Diabetes and Cystic Fibrosis Treatments Boston-based Vertex Pharmaceuticals Incorporated, a company known for its innovative approach to tackling serious diseases, has...

CASGEVY: A Groundbreaking Treatment for Genetic Blood Disorders:Vertex s CASGEVY (exa-cel) has emerged as a groundbreaking therapy for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). T...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) unveiled groundbreaking data showcasing the significant benefits of treatment with TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), known as KAFTRIO (ivacafto...

Vertex Pharmaceuticals Incorporated, a renowned biopharmaceutical company, recently presented groundbreaking data on its flagship drug TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) at the 47th European Cystic Fibrosis Con...

Cystic Fibrosis (CF) is a genetic disorder that affects the respiratory and digestive systems, impacting the lives of millions of individuals worldwide. Vertex Pharmaceuticals, a renowned biotechnology company, has made...